Table 6 Admissions and referral for patients who developed cardiovascular events in response to the antineoplastic monoclonal antibodies
Drug | Hospital admission | Emergency department visits | Cardiology clinic referral |
|---|---|---|---|
Bevacizumab (n = 81 patients) | 37 (45.7%) | 61 (75.3%) | 8 (9.8%) |
Trastuzumab (n = 71 patients) | 16 (22.5%) | 14 (19.7%) | 41 (57.7%) |
Pertuzumab combined with trastuzumab (n = 6 patients) | 0 | 0 | 1 (16.7%) |
Total (n = 158 patients) | 53 (33.5%) | 75 (47.4%) | 50 (31.6%) |